Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion type Assertion NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_head.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion wasGeneratedBy ECO_0000203 NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_provenance.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion wasDerivedFrom befree-2016 NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_provenance.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion SIO_000772 11552710 NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_provenance.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion evidence source_evidence_literature NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_provenance.
- NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_assertion description "[Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5alpha-reductase type II, CYP17, and beta-hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S-transferase M1); DNA and protein adducts; and insulin-like growth factors and leptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329824.RA2IvYmMc5qLJXvyw5DDSNv86vxERpf3hAYkOmsPpIbvM130_provenance.